Last week, we saw Moderna also release the news that their vaccine was 94.5% effective against COVID-19, meaning that it is now the second vaccine in the U.S to receive incredibly high success rates.
Moderna’s trial saw 30,000 participants involved with half given a placebo, and the other half given the vaccine. Within the group given the vaccine, similar to the Pfizer & BioNTech results, only five of them developed COVID-19. With no serious side effects, Moderna plans to begin its first vaccinations towards the end of December.
Source